Sublingual vs Injectable Peptide Bioavailability: What the Science Says

When a provider weighs an oral dissolving peptide strip against a compounded injectable, the first question is almost always the same: does the strip actually get the peptide into the body, or is it a convenience product that sacrifices absorption? It is a fair question, and the honest answer requires separating three different delivery routes that often get blended together in marketing copy. Swallowing a peptide, dissolving it under the tongue, and injecting it are not three versions of the same thing. They are three different pharmacokinetic problems. Here is what the published research supports, and where it stops.

Three Routes, Not Two

The comparison that matters is not simply "oral versus injectable." It is swallowed (gastrointestinal), oral-mucosal (sublingual and buccal), and parenteral (injection). These routes differ in the barriers a peptide must survive before it reaches systemic circulation.

The swallowed route is the harshest. A peptide taken as a capsule and swallowed has to survive stomach acid, a wall of digestive proteases, and first-pass metabolism in the liver. Review literature on oral peptide and protein delivery identifies enzymatic hydrolysis and inadequate permeation across the intestinal mucosa as the two dominant reasons systemic absorption of swallowed biologics is so low.³ This is the central reason most therapeutic peptides have historically required injection: the digestive tract is built to break peptides down into amino acids, which is exactly what you do not want when the intact peptide is the active molecule.

Injection sidesteps all of that. A subcutaneous or intramuscular injection places the peptide past the gut and past first-pass hepatic metabolism, which is why injectable delivery is the benchmark against which other routes are measured. That benchmark status is precisely why it is the standard, and also why it carries the operational cost: sterile compounding, needles, cold chain, and patient adherence friction.

Why the Oral Mucosa Is a Different Story

The sublingual and buccal routes are mechanically distinct from swallowing. The tissue under the tongue and inside the cheek is thin, richly vascularized, and drains into systemic circulation in a way that bypasses the gastrointestinal tract and the liver's first-pass metabolism. A 2025 review in Pharmaceutics describes the oral mucosa's extensive vascularization and direct systemic connection as the core reason drugs delivered this way can avoid first-pass metabolism within the gastrointestinal tract and liver.⁴ That is the mechanistic argument for the strip format: it is not asking a peptide to survive digestion, because the peptide never reaches the digestive tract in meaningful quantity.

This is more than theory. Decades of pharmaceutical work have examined whether peptides and proteins can cross the buccal mucosa, and the literature is clear that they can, by passive diffusion, with the chief barrier being the organized lipid array in the superficial epithelial layers.¹ Earlier foundational work on oral-cavity mucosal delivery reached a compatible conclusion: the buccal mucosa is suitable for delivery systems and can deliver peptide drugs, with the practical ceiling on the route set by molecular size and the availability of safe penetration enhancers.²

What the Research Does Not Say

This is where compliance-minded providers should slow down. The mechanism is well supported. A blanket claim that any sublingual peptide matches injection point-for-point on bioavailability is not. The same literature that validates oral-mucosal delivery also names its limits plainly.

Molecular weight is the first constraint. Small peptides cross the oral mucosa far more readily than large ones. As peptide size increases, passive diffusion across the epithelium drops, and the route increasingly depends on formulation help to be useful.¹ A peptide that absorbs well sublingually at one molecular weight cannot be assumed to behave the same way at another.

Residence time is the second. A molecule only absorbs while it is in contact with the mucosa. Saliva flow and swallowing constantly clear material from the mouth, which is why the research emphasizes adhesive dosage forms, gels, films, tablets, and patches, that hold the formulation against the tissue long enough for absorption to occur, often paired with absorption promoters.¹ Formulation, not just the active peptide, determines how much actually crosses.

Enzymatic activity is the third. The mouth is gentler than the gut, but it is not enzyme-free. The advantage of the oral-mucosal route is relative, not absolute, and that nuance is the difference between an accurate provider conversation and an overclaim.

So the defensible position is this: for appropriately sized peptides in a formulation designed for mucosal residence, oral-mucosal delivery has a real, research-backed mechanism for reaching systemic circulation while bypassing the barriers that defeat swallowed peptides. That is a meaningful claim. It is also a bounded one.

Reading a Bioavailability Number Honestly

Bioavailability figures get quoted loosely in this category, so it helps to know what the number means before repeating it. Bioavailability is the fraction of an administered dose that reaches systemic circulation intact. Intravenous delivery is defined as 100 percent because the dose goes straight into the blood. Every other route is measured against it.

That framing carries two implications providers should hold onto. First, a bioavailability percentage is meaningful only when it is tied to a specific peptide, a specific formulation, and a specific study. A figure measured for one molecule does not transfer to a different molecule by analogy. Second, bioavailability is not the same as clinical effect. A route can deliver a clinically useful amount of peptide without matching the raw absorbed fraction of injection, because what matters is whether enough intact peptide reaches the target, not whether the two routes are numerically identical. When you see a single bioavailability percentage applied across an entire product line, treat it as a marketing simplification rather than a per-peptide measurement.

What This Means at the Counter

For a clinic deciding between strip and injectable formats, the science supports a practical framing rather than a winner-take-all verdict.

• Route fit is peptide-specific. The oral-mucosal route is best suited to smaller peptides in mucoadhesive formulations. It is not a universal substitute for every injectable peptide, and the literature is explicit that size and formulation set the ceiling.¹²
• The mechanism advantage over swallowing is real. Bypassing digestive proteases and first-pass metabolism is the central reason the strip format is mechanistically different from a swallowed capsule, and it is the part of the story with the strongest support.³⁴
• Adherence is part of the equation. A delivery route that patients will actually use consistently has clinical value beyond its raw absorption figure. A strip a patient takes daily can outperform an injection a patient skips, which is an operational reality rather than a pharmacokinetic claim.

If your practice is comparing these routes for a specific molecule, the BPC-157 and NAD+ comparisons go deeper on two peptides where providers ask this question most often. See BPC-157 oral strips vs. injectable and NAD+ strips vs. NAD+ IV for the per-molecule detail.

The Bottom Line for Practices

Sublingual and buccal delivery is not a marketing reframe of swallowing a pill. It is a mechanically separate route with a published basis for reaching systemic circulation while avoiding the gut and the liver's first pass. The research validates the mechanism and just as clearly maps its boundaries: molecular size, mucosal residence time, and formulation quality decide how much of any given peptide actually crosses. The providers who win patient trust in this category are the ones who describe that mechanism accurately and resist the temptation to flatten it into a single number.

The oral dissolving strips in our wholesale program use patented InstaRelease® technology by InstaMed, engineered for mucosal residence and dissolution. Apply for a free wholesale account.

References

1. Senel S, Kremer M, Nagy K, Squier C. Delivery of bioactive peptides and proteins across oral (buccal) mucosa. Curr Pharm Biotechnol. 2001;2(2):175-186. PubMed: 11480421
2. Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci. 1992;81(1):1-10. PubMed: 1619560
3. Mehrotra S, Kalyan Bg P, Nayak PG, Joseph A, Manikkath J. Recent Progress in the Oral Delivery of Therapeutic Peptides and Proteins: Overview of Pharmaceutical Strategies to Overcome Absorption Hurdles. Adv Pharm Bull. 2024;14(1):11-33. PubMed: 38585454
4. Bahraminejad S, Almoazen H. Sublingual and Buccal Delivery: A Historical and Scientific Prescriptive. Pharmaceutics. 2025;17(8):1073. PubMed: 40871092

Disclaimer: This article is for educational purposes for healthcare providers and is not medical advice. Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Bioavailability and absorption vary by peptide, formulation, and individual. Providers are responsible for evaluating products and clinical use within their own scope of practice and applicable regulations.